期刊文献+

Real-time in vivo visualization of tumor therapy by a near-infrared-II Ag2S quantum dot-based theranostic nanoplatform 被引量:4

Real-time in vivo visualization of tumor therapy by a near-infrared-II Ag2S quantum dot-based theranostic nanoplatform
原文传递
导出
摘要 治疗学的功效的实时、客观的反馈将具有为肿瘤处理的大价值。这里,我们报导聪明的 Ag <潜水艇class=“ a-plus-plus ”> 2 </sub > S 基于QD 的 theranostic nanoplatform ( DOX@PEG-Ag <潜水艇class=“ a-plus-plus ”> 2 </sub > S )由把反癌症药 doxorubicin (纪录影片)装进聚乙烯获得了乙二醇涂的银硫化物量点( PEG-Ag <潜水艇class=“ a-plus-plus “> 2 </sub > S QD )通过恐水病恐水病的相互作用,展出了装载能力的高药,到 Ag 的纪录影片的 93 wt.%<潜水艇class=” a-plus-plus “> 2 </sub > S QD ),在血的长循环( t <潜水艇class=” a-plus-plus “在指向肿瘤组织以后,从 PEG-Ag 的纪录影片 < 潜水艇 class= “ a-plus-plus ” > 2 </sub > S 货物有选择地并且很快被释放进癌症房间,产生重要肿瘤抑制。由于深织物穿入和 Ag 的高时间空间的分辨率<潜水艇class=“ a-plus-plus ”> 2 </sub >在第二扇在红外线附近的窗户( NIR-II )中的 S QD 荧光, DOX@PEG-Ag <潜水艇class=“ a-plus-plus ”> 2 </sub >在了解指向过程和治疗学的功效的药的 vivo 即时的启用的 S 。我们期望那如此的新奇 theranostic nanoplatform, DOX@PEG-Ag < 潜水艇 class= “ a-plus-plus ” > 2 </sub > 与综合的药交货,治疗和评价功能, S 将为肿瘤的个性化的治疗是高度有用的。 Real-time and objective feedback of therapeutic efficacies would be of great value for tumor treatment. Here, we report a smart Ag2S QD-based theranostic nanoplatform (DOX@PEG-Ag2S) obtained by loading the anti-cancer drug doxorubicin (DOX) into polyethylene glycol-coated silver sulfide quantum dots (PEG-Ag2S QDs) through hydrophobic-hydrophobic interactions, which exhibited high drug loading capability (93 wt.% of DOX to Ag2S QDs), long circulation in blood (t1/2 = 10.3 h), and high passive tumor-targeting efficiency (8.9% ID/gram) in living mice where % ID/gram reflects the probe concentration in terms of the percentage of the injected dose (ID) per gram of tissue. After targeting the tumor tissue, DOX from PEG-AgRS cargoes was selectively and rapidly released into cancer cells, giving rise to a significant tumor inhibition. Owing to the deep tissue penetration and high spatio-temporal resolution of Ag2S QDs fluorescence in the second near-infrared window (NIR-II), the DOX@PEG-Ag2S enabled real-time in vivo reading of the drug targeting process and therapeutic efficacy. We expect that such a novel theranostic nanoplatform, DOX@PEG-Ag2S, with integrated drug delivery, therapy and assessment functionalities, will be highly useful for personalized treatments of tumors.
出处 《Nano Research》 SCIE EI CAS CSCD 2015年第5期1637-1647,共11页 纳米研究(英文版)
基金 This work was financially supported by the Chinese Academy of Sciences "Strategic Priority Research Program" (No. XDA01030200), the Ministry of Science and Technology of China (No. 2011CB965004), the National Natural Science Foundation of China (Nos. 21303249, 21301187, and 81401464), and the Natural Science Foundation of Jiangsu Province (Nos. BK2012007 and BK20130366).
关键词 肿瘤治疗 量子点 实时性 平台 纳米 诊断 体内 二硫化 in vivo imaging,Ag2S quantum dots,second near-infraredwindow fluorescence,drug delivery,tumor therapy
  • 相关文献

参考文献4

二级参考文献129

  • 1Szakacs, G.; Paterson, J. K.; Ludwig, J. A.; Booth-Genthe, C.; Gottesman, M. M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006, 5, 219-234.
  • 2Kirkin, V.; Joos, S.; Zornig, M. The role of Bcl-2 family members in tumorigenesis. Biochim. Biophys. Acta-Mol. Cell Res. 2004, 1644,229-249.
  • 3Kruh, G. D. Introduction to resistance to anticancer agents. Oncogene 2003, 22, 7262-7264.
  • 4Calderwood, S. K.; Khaleque, M. A.; Sawyer, D. B.; Ciocca, D. R. Heat shock proteins in cancer: Chaperones of tumorigenesis. Trends Biochem. Sci. 2006,31, 164-172.
  • 5Duhem, C.; Ries, F.; Dicato, M. What does multidrug resistance (MDR) expression mean in the clinic. Oncologist 1996,1,151-158.
  • 6Krishna, R.; Mayer, L. D. Multidrug resistance (MDR) in cancer: Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 2000,11,265-283.
  • 7Ferry, D. R.; Traunecker, H.; Kerr, D. J. Clinical trials of P-gJycoprotein reversal in solid tumours. Eur. J. Cancer 1996, 32A, 1070-1081.
  • 8Rowinsky, E. K.; Smith, L.; Wang, Y. M.; Chaturvedi, P.; Villalona, M.; Campbell, E.; Aylesworth, C.; Eckhardt, S. G.; Hammond, L.; Kraynak, M., et al. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDRI and MRP. J. Clin. Oncol. 1998,16,2964-2976.
  • 9Jabr-Milane, L. S.; van Vlerken, L. E.; Yadav, S.; Amiji, M. M. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev. 2008, 34, 592-602.
  • 10Moore, A.; Basilion, J. P.; Chiocca, E. A.; Weissleder, R. Measuring transferrin receptor gene expression by NMR imaging. Biochim. Biophys. Acta-Mol. Cell Res. 1998, 1402, 239-249.

共引文献33

同被引文献10

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部